Sheet 1 of 2

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 00963/1

APPLICATION NO.: 10/634,581

INFORMATION DISCLOSURE STATEMENT BY APPLICANT INVENTOR: Johnson, et al.

(Use several sheets if necessary)

Filed: 8/5/03

Group:

ILS. PATENT DOCUMENTS

Examiner						Filing Date If
Initial	Document Number	Date	Name	Class	Subclass	Appropriate
Ur/-	6,248,471					
	6,258,562					
	5,654,407					
	6,090,923					
	5,795,697					
	6,267,958					Í
	4,640,835		$\overline{}$			
	4,496,689		X			
	4,301,144				**	
	4,670,417					
	4,791,192				-	
7	6,113,906					
	5,919,455		•		•	
	5,643,575					
	5,932,462				$\overline{}$	
	6,171,586	χ			$\overline{}$	
UN-	4,816,567				$\overline{}$	

FOREIGN PATENT DOCUMENTS

Examiner							Transla	tion
Initial		Document Number	Date	Country	Class	Subclass	Yes	No
VhC	1	01/94585		PCT	·			
UK	2	788515		EP				

EXAMINER	014	DATE CONSIDERED / /
_	-4	6/18/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Form PTO-1449)

Sheet 2 of 2

FORM PTO-1449 COMMERCE, PATENT A	U.S. DEPARTMENT OF AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 00963/1	APPLICATION NO.: 10/634,581	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Johnson, et al.		
(Use several sh	neets if necessary)	Filed: 8/5/01	Group:	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
UN	7 3	Meager et al; Hybridoma; 6; 305-311; 1987
	4	Fendly et al; 6; 359-370; 1987
	5	Shimammoto et al; Immunology Letters; 17; 311-318; 1988
	6	Rankin et al; British J. Rheumatology; 34; 334-342; 1995
VA	- 7	Pikal, M.; biopharm; 3(9); 26-30; 1990
	8	Arkawa et al; Pharm Res; 8(3); 285-291; 1991
	9	Stratton, Lewis et al; J of Pharm Sci; 90(12); 2141-2148; Dec 2001
	10	Chapman, Andrew P. et al; Nature Biotechnology; 17; 780-783; August 1999
	11	Ishi, Yoshiharu et al; Biophys J.; 50; 75-80; July 1986
	12	Kohler et al; Nature; 256; 495; 1975
	13	Clackson et al; Nature; 352; 624-628; 1991
	14	Marks et al; J. Mol. Biol.; 222; 581-597; 1991
	15	Morrison et al; Proc Natl Acad Sci USA; 81; 6851-6855; 1984
Ups	_ 16	
UZ	17	Reichmann et al; Nature; 332; 323-329; 1988
_ <i>[M</i>	18	Presta; Curr Op Struct Biol.; 2; 593-596; 1992

EXAMINER SAL	DATE CONSIDERED
EXAMINEK: Initial if citation considered, whether Draw line through citation if not in conformance a next communication to applicant.	

(Form PTO-1449)